Assembly Biosciences, Inc. (NASDAQ:ASMB) Position Maintained by Bank of New York Mellon Corp

Bank of New York Mellon Corp continued to hold its stake in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,148 shares of the biopharmaceutical company’s stock at the end of the first quarter. Bank of New York Mellon Corp owned about 0.07% of Assembly Biosciences worth $310,000 as of its most recent SEC filing.

Separately, Acadian Asset Management LLC raised its stake in shares of Assembly Biosciences by 143.4% in the first quarter. Acadian Asset Management LLC now owns 10,325 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 6,083 shares during the last quarter. Hedge funds and other institutional investors own 68.88% of the company’s stock.

Assembly Biosciences, Inc. (NASDAQ:ASMB) traded up 1.18% during trading on Friday, hitting $24.87. The company had a trading volume of 57,339 shares. The stock’s market capitalization is $431.84 million. The firm’s 50 day moving average is $22.34 and its 200-day moving average is $22.88. Assembly Biosciences, Inc. has a 52-week low of $5.92 and a 52-week high of $28.24.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.com-unik.info/2017/08/19/assembly-biosciences-inc-nasdaqasmb-stake-held-by-bank-of-new-york-mellon-corp-updated.html.

A number of analysts recently issued reports on ASMB shares. Chardan Capital started coverage on Assembly Biosciences in a report on Tuesday, May 30th. They issued a “buy” rating and a $35.00 price target for the company. BidaskClub raised Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 3rd. Finally, Zacks Investment Research downgraded Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Monday.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

What are top analysts saying about Assembly Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Assembly Biosciences Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit